161 related articles for article (PubMed ID: 20557858)
1. Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
Schmitt S; Bertsch U; Goldschmidt H
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):494-6. PubMed ID: 20557858
[No Abstract] [Full Text] [Related]
2. Bortezomib (velcade) for multiple myeloma.
Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
[No Abstract] [Full Text] [Related]
3. Review. Clinical pharmacokinetics of bortezomib.
Levêque D; Carvalho MC; Maloisel F
In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib in multiple myeloma.
Terpos E; Roussou M; Dimopoulos MA
Expert Opin Drug Metab Toxicol; 2008 May; 4(5):639-54. PubMed ID: 18484921
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
6. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
[No Abstract] [Full Text] [Related]
7. Extramedullary involvement: an emerging problem in multiple myeloma.
Molica S
Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
[No Abstract] [Full Text] [Related]
8. [Bortezomib in second-line therapy].
Musch A
Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
[No Abstract] [Full Text] [Related]
9. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Prince HM; Schenkel B; Mileshkin L
Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817
[No Abstract] [Full Text] [Related]
10. Hematology: first-line bortezomib benefits patients with multiple myeloma.
Dimopoulos MA; Terpos E
Nat Rev Clin Oncol; 2009 Dec; 6(12):683-5. PubMed ID: 19942924
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor for treatment of multiple myeloma.
Ahmad K
Lancet Oncol; 2005 Aug; 6(8):546. PubMed ID: 16094754
[No Abstract] [Full Text] [Related]
12. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
13. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Tanaka T; Yamasaki R; Omura H; Hino N
Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
[No Abstract] [Full Text] [Related]
14. Bortezomib in multiple myeloma.
Vandenbroucke JP; Kroep JR
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
[No Abstract] [Full Text] [Related]
15. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
[No Abstract] [Full Text] [Related]
17. Managing light chain deposition disease.
Gertz MA
Leuk Lymphoma; 2012 Feb; 53(2):183-4. PubMed ID: 21913808
[No Abstract] [Full Text] [Related]
18. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
19. New developments with bortezomib in treating multiple myeloma.
Reddy GK
Clin Lymphoma; 2004 Mar; 4(4):215-6. PubMed ID: 15072611
[No Abstract] [Full Text] [Related]
20. Individualizing cancer therapy.
Gertz MA; Tadmor T
Leuk Lymphoma; 2010 Sep; 51(9):1585-7. PubMed ID: 20578822
[No Abstract] [Full Text] [Related]
[Next] [New Search]
